HIGHLIGHTS
- who: JHEOR and collaborators from the the Treatment Myelofibrosis in Spain Dptof, Negrín University Hospital, Las Palmas de Gran Canaria, Spain have published the research: Cost-effectiveness Ruxolitinib vs Best Available Therapy in, in the Journal: (JOURNAL)
- what: These results lie close to those achieved in the present analysis, mainly due to the similar OS-curve adjustment carried out in the analyses. The present model was improved to take into account criticisms conducted by the NICE ERG . Based on NICE recommendations, the time horizon of the analysis was reduced from 35 to 15 years . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.